Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

por de Leeuw, David C., Ossenkoppele, Gert J., Janssen, Jeroen J. W. M.
Publicado 2022

Reply to the Comment on Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis

por Polak, Tobias B., Janssen, Jeroen J. W. M., Cucchi, David G. J.
Publicado 2022

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

por Griffioen, Mila S., de Leeuw, David C., Janssen, Jeroen J. W. M., Smit, Linda
Publicado 2022

Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation

por Bouwman, Linda, Eeltink, Corien M., Visser, Otto, Janssen, Jeroen J. W. M., Maaskant, Jolanda M.
Publicado 2017

MRD Tailored Therapy in AML: What We Have Learned So Far

por Ngai, Lok Lam, Kelder, Angèle, Janssen, Jeroen J. W. M., Ossenkoppele, Gert J., Cloos, Jacqueline
Publicado 2021

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

por Verhagen, Noor E., Koenderink, Jan B., Blijlevens, Nicole M. A., Janssen, Jeroen J. W. M., Russel, Frans G. M.
Publicado 2023

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

por Jansen, Jeroen P., O’Sullivan, Amy K., Lugtenburg, Elly, Span, Lambert F. R., Janssen, Jeroen J. W. M., Stam, Wiro B.
Publicado 2010

Patient satisfaction with information on oral anticancer agent use

por Boons, Christel C. L. M., Timmers, Lonneke, van Schoor, Natasja M., Swart, Eleonora L., Hendrikse, N. Harry, Janssen, Jeroen J. W. M., Hugtenburg, Jacqueline G.
Publicado 2017

Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies

por de Jong, Greta, Janssen, Jeroen J. W. M., Biemond, Bart J., Zeerleder, Sacha S., Ossenkoppele, Gert J., Visser, Otto, Nur, Erfan, Meijer, Ellen, Hazenberg, Mette D.
Publicado 2019

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

por Kockerols, Camille C.B., Geelen, Inge, Levin, Mark-David, Janssen, Jeroen J.W.M., Dinmohamed, Avinash G., Hoogendoorn, Mels, Cornelissen, Jan J., Westerweel, Peter E.
Publicado 2022

A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts

por Smilde, Bernard J., Botman, Esmée, de Vries, Teun J., de Vries, Ralph, Micha, Dimitra, Schoenmaker, Ton, Janssen, Jeroen J. W. M., Eekhoff, Elisabeth M. W.
Publicado 2022

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study...

por de Greef, Georgine E., Braakman, Eric, van der Holt, Bronno, Janssen, Jeroen J.W.M., Petersen, Eefke, Vucinic, Vladimir, Thuss, Nicole, Grootes, Meriam, Cornelissen, Jan J.
Publicado 2018

Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis

por Polak, Tobias B., van Rosmalen, Joost, Dirven, Stijn, Herzig, Julia K., Cloos, Jacqueline, Meshinchi, Soheil, Döhner, Konstanze, Janssen, Jeroen J.W.M., Cucchi, David G.J.
Publicado 2022

Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia

por Geelen, Inge G.P., Thielen, Noortje, Janssen, Jeroen J.W.M., Hoogendoorn, Mels, Roosma, Tanja J.A., Willemsen, Sten P., Visser, Otto, Cornelissen, Jan J., Westerweel, Peter E.
Publicado 2017

Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden

por Boons, Christel C. L. M., den Hartog, Yvonne M., Janssen, Jeroen J. W. M., Zandvliet, Anthe S., Vos, René M., Swart, Eleonora L., Hendrikse, N. Harry, Hugtenburg, Jacqueline G.
Publicado 2020

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML

por Wojtuszkiewicz, Anna, van der Werf, Inge, Hutter, Stephan, Walter, Wencke, Baer, Constance, Kern, Wolfgang, Janssen, Jeroen J. W. M., Ossenkoppele, Gert J., Haferlach, Claudia, Cloos, Jacqueline, Haferlach, Torsten
Publicado 2021

Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity

por Janssen, Lando, Blijlevens, Nicole M.A., Drissen, Meggie M.C.M., Bakker, Esmée A., Nuijten, Malou A.H., Janssen, Jeroen J.W.M., Timmers, Silvie, Hopman, Maria T.E.
Publicado 2020

High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population

por Kockerols, Camille C.B., Geelen, Inge G.P., Levin, Mark-David, Janssen, Jeroen J.W.M., Beverloo, H. Berna, Dinmohamed, Avinash G., Hoogendoorn, Mels, Cornelissen, Jan J., Westerweel, Peter E.
Publicado 2023

A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands

por Claudiani, Simone, Janssen, Jeroen J. W. M., Byrne, Jenny, Smith, Graeme, Blijlevens, Nicole, Raghavan, Manoj, Smith, Matthew, Clark, Richard E., Mclain‐Smith, Susan, Carter, Angela M., Milojkovic, Dragana, Apperley, Jane F.
Publicado 2022

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018

por Maas, Carolien C. H. M., van Klaveren, David, Ector, Geneviève I. C. G., Posthuma, Eduardus F. M., Visser, Otto, Westerweel, Peter E., Janssen, Jeroen J. W. M., Blijlevens, Nicole M. A., Dinmohamed, Avinash G.
Publicado 2021